Analysts have been eager to weigh in on the Healthcare sector with new ratings on Humana (HUM – Research Report), Ocular Therapeutix (OCUL – Research Report) and Amarin (AMRN – Research Report).
Humana (HUM)
In a report issued on November 1, Ann Hynes from Mizuho Securities maintained a Buy rating on Humana, with a price target of $550.00. The company’s shares closed last Friday at $477.01.
According to TipRanks.com, Hynes is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Humana with a $589.81 average price target, which is a 23.3% upside from current levels. In a report issued on November 1, Deutsche Bank also maintained a Buy rating on the stock with a $614.00 price target.
See today’s best-performing stocks on TipRanks >>
Ocular Therapeutix (OCUL)
Robert W. Baird analyst Colleen M. Kusy maintained a Buy rating on Ocular Therapeutix on November 1 and set a price target of $18.00. The company’s shares closed last Friday at $3.26.
According to TipRanks.com, Kusy ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
Currently, the analyst consensus on Ocular Therapeutix is a Strong Buy with an average price target of $13.40, representing a 298.8% upside. In a report issued on October 17, JMP Securities also reiterated a Buy rating on the stock with a $12.00 price target.
Amarin (AMRN)
Leerink Partners analyst Roanna Ruiz maintained a Hold rating on Amarin on November 1 and set a price target of $2.00. The company’s shares closed last Friday at $0.73, close to its 52-week low of $0.65.
According to TipRanks.com, Ruiz has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Amarin has an analyst consensus of Hold, with a price target consensus of $1.50, representing a 121.6% upside. In a report issued on October 25, Jefferies also downgraded the stock to Hold with a $1.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on HUM:
- Humana price target lowered to $570 from $575 at Stephens
- Humana ‘committed’ to 2025 adjusted EPS target of $37.00
- Humana backs FY23 adjusted EPS view to ‘at least’ $28.25, consensus $28.30
- ON Semiconductor, Array Technologies removed from ‘ US 1’ list at BofA
- Humana reports Q3 adjusted EPS $7.78, consensus $7.16
